Research · 2026-08-17
Kratom's Main Alkaloid Reduced Methamphetamine-Seeking in Rats, Study Finds
Source: Kratom.news (reporting on Psychopharmacology study)
Why it matters
With no FDA-approved medication for methamphetamine use disorder, early evidence that a kratom-derived alkaloid can selectively reduce drug-seeking behavior, without blunting motivation for food, points to a possible treatment lead worth further study.
The big picture
The Psychopharmacology study arrives amid a broader research effort separating kratom's dominant leaf alkaloid, mitragynine, from 7-hydroxymitragynine (7-OH), the more potent, opioid-receptor-binding metabolite driving most current regulatory and enforcement action, including an NIDA-supported Phase 1 human trial of purified mitragynine (MG001) now weeks from its first dose.
Key findings
- Researchers from Rutgers, Texas Tech University Health Sciences Center, and the University of Florida trained rats to self-administer intravenous methamphetamine under fixed- and progressive-ratio schedules.
- Mitragynine reduced methamphetamine self-administration dose-dependently, lowering active lever presses, infusions, and "breakpoints" (the maximum effort animals would exert for a dose).
- Effects were broadly similar across male and female rats, though sample sizes were too small to confirm sex differences.
- In a separate food-reinforcement experiment, the same mitragynine doses that cut methamphetamine-seeking did not reduce food pellets earned, suggesting selective rather than blanket behavioral suppression.
- The study used purified, controlled doses of isolated mitragynine, not the variable commercial powders, extracts, or shots sold at retail.
What they say
"Mitragynine reduced methamphetamine-seeking in rats while leaving food-maintained responding intact, behavioral selectivity in an animal model, not evidence of a treatment in people," the researchers said, per the Rutgers Brain Health Institute summary.
Bottom line
**A purified kratom alkaloid cut meth-seeking behavior in rats without dulling their drive to eat, a preclinical signal worth testing further, not a reason to self-treat with kratom.**